Gregory Lucier Purchases 50,000 Shares of Avantor (NYSE:AVTR) Stock

Avantor, Inc. (NYSE:AVTR) Director Gregory Lucier bought 50,000 shares of the stock in a transaction on Thursday, February 19th. The stock was purchased at an average price of $9.16 per share, for a total transaction of $458,000.00. Following the completion of the purchase, the director directly owned 50,000 shares in the company, valued at approximately $458,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Avantor Stock Up 2.4%

AVTR opened at $9.10 on Wednesday. The firm has a market capitalization of $6.21 billion, a P/E ratio of -11.67, a price-to-earnings-growth ratio of 3.50 and a beta of 0.94. Avantor, Inc. has a one year low of $8.83 and a one year high of $18.02. The company has a fifty day moving average price of $11.10 and a 200-day moving average price of $12.07. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.18.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.01. Avantor had a positive return on equity of 10.45% and a negative net margin of 8.09%.The company had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter last year, the business posted $0.27 earnings per share. The firm’s revenue was down 1.4% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.770-0.830 EPS. Equities research analysts expect that Avantor, Inc. will post 1.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AVTR. Bank of America cut shares of Avantor from a “buy” rating to a “neutral” rating and set a $13.00 price objective on the stock. in a research report on Monday, December 15th. Barclays decreased their price target on shares of Avantor from $12.00 to $9.00 and set an “equal weight” rating on the stock in a report on Thursday, February 12th. Raymond James Financial cut shares of Avantor from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 4th. Zacks Research lowered shares of Avantor from a “hold” rating to a “strong sell” rating in a research report on Friday, February 13th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $12.00 price target (down from $14.00) on shares of Avantor in a research report on Thursday, October 30th. Three analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $11.83.

Institutional Trading of Avantor

Several hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP bought a new position in shares of Avantor during the fourth quarter valued at about $268,584,000. Greenhaven Associates Inc. bought a new stake in shares of Avantor in the 3rd quarter valued at about $228,528,000. Dodge & Cox boosted its holdings in Avantor by 17.1% during the 2nd quarter. Dodge & Cox now owns 117,433,484 shares of the company’s stock valued at $1,580,655,000 after acquiring an additional 17,170,761 shares during the period. London Co. of Virginia bought a new position in Avantor during the 3rd quarter worth approximately $159,669,000. Finally, Morgan Stanley grew its position in Avantor by 179.4% during the 4th quarter. Morgan Stanley now owns 17,468,418 shares of the company’s stock worth $200,188,000 after acquiring an additional 11,216,565 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

Avantor Company Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.